Rituximab Versus Cyclophosphamide for Rheumatoid Vasculitis
A rare, organ-threatening complication of long-standing rheumatoid arthritis forces a choice between two drugs whose evidence has never had, and likely will never have, a randomized trial to settle it.
Robert 'Bob' S., a 69-year-old man, has spent nearly every weekend of his retirement on the river with a fly rod, a habit he picked up from his father and has since passed on to two of his grandchildren. His rheumatoid arthritis is twenty-two years old, largely predating the biologic era, and has left him with substantial joint damage from years before better treatment became available. Over the past three weeks, he's developed two new findings his rheumatologist immediately recognized as more serious than a joint flare: painful ischemic ulcers on two fingertips, and a new right foot drop consistent with mononeuritis multiplex. A nerve and skin biopsy confirmed necrotizing vasculitis of small-to-medium vessels — rheumatoid vasculitis, a rare, potentially organ- and tissue-threatening complication of long-standing disease that has become considerably less common since biologic therapy improved routine disease control.
That same rarity is why the evidence for treating it has never advanced past registry and case-series data, and likely never will: the disease is now too uncommon in the biologic era to support a randomized trial powered to compare treatments directly. Historically, cyclophosphamide, borrowed from ANCA-associated vasculitis induction regimens, was the default treatment for severe presentations. More recent evidence, largely from the French AIR registry, has found rituximab an effective alternative for many rheumatoid vasculitis presentations, with a meaningfully better long-term toxicity profile — sparing patients cyclophosphamide's real risks of infertility, bladder toxicity, and cumulative malignancy risk with repeated courses. What that registry data doesn't cleanly settle is whether his specific presentation, with active nerve and digital tissue at risk, sits closer to the more severe end of the spectrum where some case-series experience suggests cyclophosphamide's broader immunosuppression may act faster than rituximab's more targeted, B-cell-restricted mechanism.
Choosing induction for a rare, organ-threatening flare
I'd start rituximab first. The French AIR registry, the largest look anyone has taken at treated rheumatoid vasculitis, found it an effective option with a substantially better long-term toxicity profile than cyclophosphamide — no infertility risk, no bladder toxicity, less cumulative malignancy risk from repeated exposure. At his age, and given what he's told us about wanting to stay active and independent, that long-term profile matters.
I'd want to weigh the severity of what's actually in front of us more heavily. This isn't a limited cutaneous presentation — he has mononeuritis multiplex and digital ischemia, both genuinely organ- and tissue-threatening findings. Some case-series experience with the most severe rheumatoid vasculitis presentations suggests cyclophosphamide's broader immunosuppression may act faster than rituximab's more targeted, B-cell-restricted mechanism, which matters when active nerve and tissue damage is already underway.
I want to be honest that neither of our positions rests on anything better than registry and case-series data — there's no randomized trial comparing these drugs for this disease, and given how rare it's become, there's unlikely ever to be one. I'm not claiming certainty that cyclophosphamide works faster here, only that the severity of his presentation is a real reason to weigh that possibility seriously rather than defaulting to the drug with the better long-term safety profile.
Given that, I'd support trying rituximab first as you're proposing, but only with a genuinely short, pre-specified checkpoint given how active his nerve involvement is — not the longer assessment window we'd use for joint disease.
Agreed: rituximab started alongside high-dose glucocorticoids, with a short, pre-specified clinical checkpoint given the urgency of his mononeuritis multiplex, and cyclophosphamide named explicitly as the next step if objective improvement isn't seen by that point rather than treated as an unlikely fallback.
Not agreed: whether his presentation's severity should have shifted the first-line choice toward cyclophosphamide outright. The vasculitis specialist's position, grounded in case-series experience with the most severe presentations, was not overruled, only outweighed for now by the rheumatologist's weighting of long-term toxicity and Bob's own stated priorities — both voices agreed the short checkpoint exists specifically because that disagreement was never actually resolved.